- Home
- PMEC vs COEP Comparison
PMEC vs COEP Comparison
Compare PMEC & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | COEP |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 100.4M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | PMEC | COEP |
|---|---|---|
| Price | $1.08 | $15.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 193.2K | 74.3K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | $500,996.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $2.31 |
| 52 Week High | $2.44 | $21.41 |
Technical Indicators
Market Signals| Indicator | PMEC | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 47.72 |
| Support Level | $0.97 | $15.40 |
| Resistance Level | $1.10 | $16.80 |
| Average True Range (ATR) | 0.09 | 1.57 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 58.54 | 20.64 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.